References Albert SM. Projecting neurologic disease burden: difficult but critical. Neurology. 2007;68(5):322-3. Brunner D, Balci F, Ludvig EA. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration. Behav Processes. 2012;89(2):187-95. Chico LK, Van Eldik LJ, Watterson DM. Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov. 2009;8(11):892-909. Craven R. The risky business of drug development in neurology. Lancet Neurol. 2011;10(2):116-7. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational agents. Clin Pharmacol Ther. 2010;87(3):272-277. Disease Control Priorities Project. Mental and neurological disorders. Available at: http://www.dcp2.org/file/60/DCPP--Mental%20Health.pdf. Accessed 31 January 2012. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-6. Editorial. A grand plan for Alzheimer’s disease and related dementias. Lancet Neurol. 2012;11(3):201. Gomez-Mancilla B, Marrer E, Kehren J, et al. Central nervous system drug development: an integrative biomarker approach toward individualized medicine. NeuroRx. 2005;2(4):683-95. Hall PS, McCabe C, Brown JM, Cameron DA. Health economics in drug development: efficient research to inform healthcare funding decisions. Eur J Cancer. 2010;46(15):2674-80. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the “common” neurologic disorders? Neurology. 2007;68(5):326-37.